0001415889-24-002394.txt : 20240202 0001415889-24-002394.hdr.sgml : 20240202 20240202183154 ACCESSION NUMBER: 0001415889-24-002394 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LaSpaluto Michelle CENTRAL INDEX KEY: 0002001106 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35867 FILM NUMBER: 24593316 MAIL ADDRESS: STREET 1: C/O CHIMERIX, INC. STREET 2: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHIMERIX INC CENTRAL INDEX KEY: 0001117480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330903395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919.806.1074 MAIL ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 4 1 form4-02022024_110246.xml X0508 4 2024-02-01 0001117480 CHIMERIX INC CMRX 0002001106 LaSpaluto Michelle C/O CHIMERIX, INC. 2505 MERIDIAN PARKWAY, SUITE 100 DURHAM NC 27713 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2024-02-01 4 A 0 25000 0 A 112939 D Stock Option (Right to Buy) .93 2024-02-01 4 A 0 150000 0 A 2034-01-31 Common Stock 150000 150000 D The shares being reported are being issued pursuant to restricted unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 6,250 shares subject to the RSUs will vest on the one-year anniversary of the date of grant, 6,250 shares subject to the RSUs will vest on the second-year anniversary of the date of grant, 6,250 shares subject to the RSUs will vest on the third-year anniversary of the date of grant, and 6,250 shares subject to the RSUs will vest on the fourth-year anniversary of the date of grant. 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. /s/ Michael Alrutz, Attorney-in-Fact 2024-02-02